Flavien Charpentier

This program aims to identify therapeutic targets in the signaling pathways involved in the development of fibrosis during aging in hereditary forms of progressive cardiac conduction disease
(PCCD). It is based on pharmacological studies performed on a mouse model of SCN5A-related PCCD and on studies aimed at identifying the role of the SCN5A gene product, the main cardiac sodium channel NaV1.5, in cardiac fibroblasts.